Skip to main content
. 2015 Feb 20;16(3):4416–4428. doi: 10.3390/ijms16034416

Table 1.

Pharmacologic substrates, inhibitors and inducers of cytochrome P450 (CYP2D6) of relevant psychotropic drugs.

Substrate Inhibitors Inducers
Acetaminophen Amiodarone Dexamethasone
Amphetamine-Dextroamphetamine Bupropion Rifampin
Aripiprazole Celecoxib
Atomoxetine Chlorpheniramine
Clonidine Chlorpromazine
Codeine * Citalopram
Dextromethorphan Clozapine
Duloxetine Cocaine
Fluoxetine Desipramine
Fluvoxamine Diphenhydramine
Haloperidol Duloxetine
Iloperidone Fluoxetine
Methadone Halofantrine
Methamphetamine Haloperidol
Mirtazapine Hydroxychloroquine
Nefazodone Imatinib
Olanzapine Imipramine
Paroxetine Levomepromazine
Phenothiazines Methadone
Risperidone * Metoclopramide
Sertraline Mibefradil
Tricyclic antidepressants (TCAs) Moclobemide
Tramadol Nelfinavir
Venlafaxine * Norfluoxetine
Vortioxetine Paroxetine
Perphenazine
Quinidine
Ranitidine
Ritonavir
Sertraline
Terbinafine
Thioridazine
Tranylcypromine

Phenothiazines include: Chlorpromazine, fluphenazine, perphenazine, promethazine, thioridazine; tricyclic antidepressants include: Amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine; * Metabolized to active compound; ω-3 fatty acids can inhibit CYP2D6 activity at high doses [28]; Compounds prescribed for our clinical case are indicated in bold. Table revised from literature supplied by Genomind, LLC (www.genomind.com).